Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases

BACKGROUND: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Despite extensive laboratory and imaging efforts, the primary site usually cannot be unequivocally confirmed, and the treatment for the most part remains empirical. Recently, identification of common cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatalica, Zoran, Millis, Sherri Z., Vranic, Semir, Bender, Ryan, Basu, Gargi D., Voss, Andreas, Von Hoff, Daniel D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2014
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322997/
https://www.ncbi.nlm.nih.gov/pubmed/25415047

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322997/
https://www.ncbi.nlm.nih.gov/pubmed/25415047

Ejemplares similares